Cargando…
Heart dose and cardiac comorbidities influence death with a cardiac cause following hypofractionated radiotherapy for lung cancer
BACKGROUND: There is increasing evidence of cardiac toxicity of thoracic radiotherapy however, it is difficult to draw conclusions on cardiac dose constraints due to the heterogeneity of published studies. Moreover, few studies record data on cause of death. The aim of this paper is to investigate t...
Autores principales: | Banfill, Kathryn, Abravan, Azadeh, van Herk, Marcel, Sun, Fei, Franks, Kevin, McWilliam, Alan, Faivre-Finn, Corinne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592751/ https://www.ncbi.nlm.nih.gov/pubmed/36303830 http://dx.doi.org/10.3389/fonc.2022.1007577 |
Ejemplares similares
-
Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy
por: Abravan, Azadeh, et al.
Publicado: (2022) -
Dose surface maps of the heart can identify regions associated with worse survival for lung cancer patients treated with radiotherapy
por: McWilliam, Alan, et al.
Publicado: (2020) -
Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions
por: Banfill, Kathryn, et al.
Publicado: (2021) -
Radial Data Mining to Identify Density–Dose Interactions That Predict Distant Failure Following SABR
por: Davey, Angela, et al.
Publicado: (2022) -
Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence
por: Davey, Angela, et al.
Publicado: (2023)